Our top pick for
China Customer Relations Centers Inc is an information technology services business based in the US. China Customer Relations Centers shares (CCRC) are listed on the NASDAQ and all prices are listed in US Dollars. China Customer Relations Centers employs 14,057 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.96|
|52-week range||$6.48 - $6.50|
|50-day moving average||$6.27|
|200-day moving average||$5.46|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.36|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-26)||N/A|
|1 month (2022-06-03)||N/A|
|3 months (2022-04-03)||N/A|
|6 months (2022-01-03)||N/A|
|1 year (2021-07-06)||-8.31%|
|2 years (2020-07-07)||22.38%|
|3 years (2019-07-05)||9.89|
|5 years (2017-07-07)||13.65|
Valuing China Customer Relations Centers stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of China Customer Relations Centers's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
China Customer Relations Centers's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, China Customer Relations Centers shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
China Customer Relations Centers's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $27.9 million.
The EBITDA is a measure of a China Customer Relations Centers's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$240.3 million|
|Operating margin TTM||9.91%|
|Gross profit TTM||$51.6 million|
|Return on assets TTM||12.28%|
|Return on equity TTM||30.98%|
|Market capitalisation||$119.1 million|
TTM: trailing 12 months
We're not expecting China Customer Relations Centers to pay a dividend over the next 12 months.
Over the last 12 months, China Customer Relations Centers's shares have ranged in value from as little as $6.48 up to $6.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while China Customer Relations Centers's is 0.6011. This would suggest that China Customer Relations Centers's shares are less volatile than average (for this exchange).
China Customer Relations Centers, Inc. provides business process outsourcing services for transportation, e-commerce, banks and insurance, and telecommunications companies in the People's Republic of China. It offers voice-based and online-based customer care services, including customer relationship management, technical support, sales, customer retention, marketing surveys, and research, as well as artificial intelligence customer care services. The company also provides employee leasing outsourcing services to clients. China Customer Relations Centers, Inc. was incorporated in 2014 and is headquartered in Taian, the People's Republic of China. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.